Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer
Tools
Sharp, A., Welti, J., Blagg, J., de Bono, J. S.
(2016)
Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
CLINICAL CANCER RESEARCH, 22 (17).
pp. 4280-4282.
ISSN 1078-0432
Full text not available from this repository.
A copy of the full text may be available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC53021...
Abstract
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. (C) 2016 AACR.
Item Type: | Editorial |
---|---|
Authors (ICR Faculty only): | De Bono, Johann and Blagg, Julian |
All Authors: | Sharp, A., Welti, J., Blagg, J., de Bono, J. S. |
Additional Information: | ISI Document Delivery No.: DV6IR Times Cited: 0 Cited Reference Count: 12 Sharp, Adam Welti, Jonathan Blagg, Julian de Bono, Johann S. 0 AMER ASSOC CANCER RESEARCH PHILADELPHIA CLIN CANCER RES |
Uncontrolled Keywords: | DOMAIN |
Research teams: | ICR divisions > Cancer Therapeutics > Medicinal Chemistry 1 (including Analytical Chemistry and In Silico Chemistry) ICR divisions > Cancer Therapeutics > Cancer Biomarkers ICR divisions > Clinical Studies > Cancer Biomarkers ICR divisions > Clinical Studies > Prostate Cancer Targeted Therapy Group |
Depositing User: | Barry Jenkins |
Date Deposited: | 14 Oct 2016 15:00 |
Last Modified: | 10 Jul 2017 15:17 |
URI: | http://publications.icr.ac.uk/id/eprint/15357 |
Actions (login required)
![]() |
View Item |